Zhi-min, X., Qiu-fen, L., Mei-hua, Z. et al. Observation on therapeutic effects of Shengmai powder in treating acute viral myocarditis., Chin. J. Integr. Med. 10, 86–90 (2004). https://doi.org/10.1007/BF02836373
Xu Zhi-min, Lu Qiu-fen, Zhao Mei-hua, et al. Observation on therapeutic effects of Shengmai powder in treating acute viral myocarditis. [J]. Chinese Journal of Integrative Medicine 10(2):86-90(2004)
Zhi-min, X., Qiu-fen, L., Mei-hua, Z. et al. Observation on therapeutic effects of Shengmai powder in treating acute viral myocarditis., Chin. J. Integr. Med. 10, 86–90 (2004). https://doi.org/10.1007/BF02836373DOI:
Xu Zhi-min, Lu Qiu-fen, Zhao Mei-hua, et al. Observation on therapeutic effects of Shengmai powder in treating acute viral myocarditis. [J]. Chinese Journal of Integrative Medicine 10(2):86-90(2004) DOI: 10.1007/BF02836373.
Observation on therapeutic effects of Shengmai powder in treating acute viral myocarditis
摘要
Objective: To evaluate the clinical efficacy of Shengmai Powder (SMP) in treating acute viral myocarditis objectively.Methods: One hundred and twenty-four patients with acute viral myocarditis were randomized into the treated group (SMG
n = 64) and the control group (CG
n = 60). Such myocardial nutrient medicine as ATP
CoA
Vit-C
were given to both groups. And to the treated group
40 ml of Shengmai Injection per day was given intravenously for 2 weeks
which was followed by oral intake of Shengmai granule
one package three times daily for another 2 weeks in total. The same anti-arrhythmia agents were applied to both groups
and no fructose-1
6-diphosphate (FDP) for either. Semi-quantitative scoring method was adopted to observe such symptoms as chest stuffiness
palpitation and chest pain before treatment and four weeks after treatment. Meanwhile
ECG
dynamic ECG by Holter monitor
left ventricular enddiastolic dimension (LVEDD)
left ventricular ejection fraction (LVEF)
serum neutralizing antibody of virus Coxsackie B
cardiac troponin I (cTnl) and cardiac troponin T (cTnT) were examined.Results: (1) Compared with the control group
more significant improvement was got in SMG in respects of chest stuffiness
palpitation
chest pain and arrhythmia (P<0.05 orP<0.01). (2) Negative converting rates of cTnl
cTnT in the two groups were 59.46% vs 35.48%
68.75% vs 42.31% respectively (P<0.05). (3) LVEDD before and after treatment in SMG was 52. 44 ± 3. 40 mm and 48. 81 ± 2. 23mm respectively
while that in the control group was 52.31 ± 3. 74 mm and 49. 92 ± 2. 67mm respectively; LVEF before and after treatment in SMG was 60.67 ± 4.62% and 65. 02 ± 4.16% respectively
while that in the control group was 60. 91± 4.26% and 63.67 ± 3.17%. There was obvious improvement in the two parameters in both groups
but the improvement in SMG was superior to that in the control group (P<0.05).Conclusion: SMP shows a good effect in improving clinical symptoms and signs
heart function
abnormal ECG and inflammatory injury indexes in patients with acute viral myocarditis.
Abstract
Objective: To evaluate the clinical efficacy of Shengmai Powder (SMP) in treating acute viral myocarditis objectively.Methods: One hundred and twenty-four patients with acute viral myocarditis were randomized into the treated group (SMG
n = 64) and the control group (CG
n = 60). Such myocardial nutrient medicine as ATP
CoA
Vit-C
were given to both groups. And to the treated group
40 ml of Shengmai Injection per day was given intravenously for 2 weeks
which was followed by oral intake of Shengmai granule
one package three times daily for another 2 weeks in total. The same anti-arrhythmia agents were applied to both groups
and no fructose-1
6-diphosphate (FDP) for either. Semi-quantitative scoring method was adopted to observe such symptoms as chest stuffiness
palpitation and chest pain before treatment and four weeks after treatment. Meanwhile
ECG
dynamic ECG by Holter monitor
left ventricular enddiastolic dimension (LVEDD)
left ventricular ejection fraction (LVEF)
serum neutralizing antibody of virus Coxsackie B
cardiac troponin I (cTnl) and cardiac troponin T (cTnT) were examined.Results: (1) Compared with the control group
more significant improvement was got in SMG in respects of chest stuffiness
palpitation
chest pain and arrhythmia (P<0.05 orP<0.01). (2) Negative converting rates of cTnl
cTnT in the two groups were 59.46% vs 35.48%
68.75% vs 42.31% respectively (P<0.05). (3) LVEDD before and after treatment in SMG was 52. 44 ± 3. 40 mm and 48. 81 ± 2. 23mm respectively
while that in the control group was 52.31 ± 3. 74 mm and 49. 92 ± 2. 67mm respectively; LVEF before and after treatment in SMG was 60.67 ± 4.62% and 65. 02 ± 4.16% respectively
while that in the control group was 60. 91± 4.26% and 63.67 ± 3.17%. There was obvious improvement in the two parameters in both groups
but the improvement in SMG was superior to that in the control group (P<0.05).Conclusion: SMP shows a good effect in improving clinical symptoms and signs
heart function
abnormal ECG and inflammatory injury indexes in patients with acute viral myocarditis.
Wei SK, Rong YZ, Huang GF, et al. Shenmaisan’s protection from reperfusion injury on ischemic myocardial cell. Chin J Integr Tradit West Med 1991; 11 (Supple): 172–174.
Lu BJ, Rong YZ, Zhu XY, et al. Shenmaisan granules’ effect on myocardial ischemia and anti-free radicals in coronary heart disease. Acta Universitatis Medicinalis Secondae Shanghai 1999; 19(4): 319–321.
Organizing Committee of National Symposium on Myocarditis and Cardiomyopathy. Minute of National Symposium on cardiomyopathy and myocarditis. J Clin Cardiol 1995; 11(6): 324–326.
Xong DD. Progress of study on role of virus mediated myocardial injury in the pathogenesis of myocarditis. Adv Cardiol 1999; 20(3): 156–159.
Shen CH, Li TY, Cao DX, et al. Effects of combined use of Shengmai San and Liquorice decoction on cultured myocardial cells of rat infected by Coxsachia B3 virus. Medical Bulletin of Yanbian University 2001; 12(4): 272–277.
Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardial troponin I associated with myocarditis experimental and clinical correlates. Circulation 1997; 95: 163–168.
Lu QF, Zhao MH, Xu ZM, et al. Exploration on severity judgment of inflammatory myocardial injury and prognosis preindication by serum cTnl detection in viral myocarditis. J Clin Cardiol 2000; 10(16): 438–439.
Zhao MH, Rong YZ, Lu BJ, et al. Effects of Shengmai San on serum lipid peroxidation in patients with acute viral myocarditis. Chin J Integr Tradit West Med 1996; 16(3): 142–145.
Zhang YC, Rong YZ, Lu BJ, et al. Effects of Shengmai San on lipid peroxidation and it induced calcium overload in intoxicated myocardial cells. Chin J Integr Tradit West Med 1997; 17(1) > 26–28.
Yu W, Feng ZQ, Lu LP, et al. Dynamic observation on effects of Shengmai San injection on arrhythmia caused by pitresin induced myocardial ischemia. J Luzhpu Med School 1995; 18(2): 91–92.
Bi XS, Zhang WY. Controlled observation of Shengmai Injection combined with propafenone in treating arrhythmic cardiomyopathy. J Ningxia Med 1999; 21 (10): 631–632.
Zhou SM, Tai ZB, Wang XM, et al. Effects of Shengmai Injection on atrial natriuretic peptide (ANP) level in patients with acute viral myocarditis. J Clin Cardiol 2000; 16(3): 106–107.